UBS raises Iovanace Biotherapeutics price target to $8 on revenue outlook
Read the full story on Investing.com →
Opens the original article on www.investing.com
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.